Core Viewpoint - The company Brainstorm Aurora-B (06681) has entered a strategic cooperation agreement with Singapore's Lehasiba Health Management Group to promote and expand its digital health products in the Singapore market [1] Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion collaboration in Singapore [1] - Brainstorm Aurora will localize its cognitive impairment digital therapy products, support system implementation, and provide personnel training [1] - Lehasiba will utilize its offline stores and member resources to recommend the company's products to target users and manage the entire service process, including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market [1] - The collaboration aims to promote the company's products into leading private hospitals and public hospital systems in Singapore, enhancing the application and popularity of the products within the local healthcare system [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources for targeted recommendations and full-service support [2]. - Market expansion efforts will involve integrating resources such as products, channels, brands, and technology to penetrate Singapore's healthcare system, focusing on private and public hospitals [2]. Group 2: Long-term Development Opportunities - This partnership is expected to enhance the company's international presence and expand into Southeast Asia, building on previous experiences in Hong Kong and Macau [3]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and expedite product integration into local medical institutions, thereby broadening its market reach [3].

Group 1: IPO Updates - Qingsong Health Group officially listed on the Hong Kong Stock Exchange on December 23, 2025, under the stock code "2661" [3] - The company issued 26,540,000 shares, with a subscription rate of 1,421.47 times for the Hong Kong public offering and 2.9 times for the international offering [3] - The funds raised will be used for AI technology upgrades, health service expansion, and industry chain integration [4] Group 2: Company Profiles - Qingsong Health Group, established in 2014, operates as a one-stop digital health and insurance service platform, ranking 10th in China's digital health service market by revenue in 2024 [4] - Wallran Technology plans to list on the Hong Kong Stock Exchange on January 2, 2026, as the "first GPU stock" in Hong Kong, with an expected fundraising of between HKD 4.21 billion and HKD 4.85 billion [6][7] - Wallran Technology's revenue is projected to grow from CNY 499,000 in 2022 to CNY 337 million in 2024, with a compound annual growth rate of 2,500% [8] Group 3: Financial Performance - Wallran Technology has secured sales agreements worth approximately CNY 1.2407 billion, indicating strong future revenue potential [9] - Stone Technology, a leading smart vacuum cleaner brand, reported revenue exceeding CNY 12 billion and a net profit of over CNY 1 billion in the first three quarters of this year [13] - Ruipai Pet's revenue for the first half of 2025 was CNY 943 million, an increase of 8.5% compared to the same period in 2024 [21] Group 4: Market Position - Stone Technology holds a 23.4% market share by GMV and 16.7% by sales in the smart vacuum cleaner market in 2024 [12] - Ruipai Pet is the second-largest pet medical service provider in China, with 548 operating pet hospitals across 70 cities [19] - Vision Technology ranks second globally in the shipment of silicon-based OLED products for XR devices, capturing 35.2% of the market share [17] Group 5: Future Prospects - Vision Technology has established key partnerships with major clients and aims to deliver millions of silicon-based OLED micro-displays annually starting in 2026 [17] - Tongxin Medical is focused on innovative solutions for advanced heart failure treatment and has received regulatory approvals for its implantable heart devices in China and the U.S. [24] - Cloud Deep Technology is advancing in the field of embodied intelligence, with successful applications in various industries, including emergency response and industrial operations [30]

近日，微医控股凭借在数字健康领域的系统性创新和AI医疗垂直领域的卓越实践，连获两项权威殊 荣：蓝鲸新闻2025鲸潮奖"年度创新领航企业"和格隆汇金格奖"年度卓越人工智能应用企业"。 作为国际领先的AI医疗平台，微医控股创新建设运营"AI健共体"，构建了"按健康结果付费"的服务模 式，成功推动"价值医疗"实现规模化落地。该模式不仅帮助超百万用户实现健康指标改善，更形成了清 晰的商业化路径，为行业提供了从技术突破到产业赋能的系统性解决方案。 AI健共体驱动价值医疗，获评"年度创新领航企业" 12月22日，在格隆汇"金格奖"年度卓越公司评选中，微医控股获评"年度卓越人工智能应用企业"。该奖 项旨在表彰在人工智能领域实现技术突破、指引未来发展路径的领先公司。 格隆汇指出，获奖企业成功将AI技术应用到新的或现有场景中，创造出显著的商业与社会价值。微医 控股依托"AI健共体"提供健康管理会员服务，截至2025年6月30日，该服务已覆盖约110万名健康会员， 形成"健康会员制+高附加值服务"的成熟体系。2025年上半年，公司AI医疗服务收入达28.41亿元，同比 增长97.3%，展现出强劲的商业成长性。 基于自研医疗大模型 ...

专题：四大证券报精华 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ "对明年的权益市场依旧乐观！"多位基金经理在近期的策略会上公开发声。近期，国泰基金、招商基 金、汇丰晋信基金、长城基金等多家公募机构召开了2026年年度策略会，多位基金经理围绕AI科技、 消费、创新药等多个热门板块的投资机遇展开深度探讨。 融创中国全面境外债务重组完成 彻底化解了债务风险 融创中国境外债务重组迎来新进展。12月23日晚，融创中国公告，公司约96亿美元的现有债务已获全面 解除及免除。公司表示，全面境外债务重组的完成，彻底化解了公司的债务风险。在境外债务重组落地 之前，融创154亿元境内公开债券重组也已完成。截至目前，融创通过境内外债务重组，整体偿债压力 预计下降近600亿元。 华夏幸福最新公告！审议通过调整修订《股东会议事规则》的议案 华夏幸福12月23日晚间公告，公司于12月23日召开第八届董事会第三十七次会议，审议通过了平安人寿 关于调整修订《股东会议事规则》的提案。12月22日晚，华夏幸福公告称，公司董事会会议否决了股东 平安人寿意图增加的五项临时提案。记者注意到，23日的这项提案与此前五项提案 ...

具体来看，公司以自主研发的AIcare 技术体系为核心，将AI能力应用于健康内容生成、风险评估、智 能承保、理赔审核及用户运营等关键场景，显著提升服务效率与转化能力。在此基础上，轻松健康构建 起覆盖"检、医、药、康、险"的全链条数字健康服务生态，实现健康管理与保险保障的深度融合。这一 模式被市场视为AI在健康产业中实现规模化、可持续落地的重要创新方向。 从盘面结构看，轻松健康上市首日的上涨伴随着持续成交与资金承接，显示出较强的买盘支撑。业内人 士指出，在当前港股新股市场分化明显的背景下，能够获得资金持续追捧的新股，往往具备清晰的行业 定位与差异化优势。轻松健康在数字健康赛道中的稀缺属性，以及其AI技术的实际应用成果，是推动 资金集中配置的重要原因。 分析人士认为，首日股价的强劲表现，更多反映的是资本市场对公司中长期价值的预期。随着AI技术 在健康服务领域持续深化应用，具备用户基础、技术能力与全链条服务优势的平台型企业，有望在行业 竞争中率先受益。 采写：南都N视频记者 黄大乐 12月23日，轻松健康集团（2661.HK）正式登陆港交所主板，上市首日股价表现强劲。开盘即高开后持 续走强，盘中一度拉升至近60港元 ...

具体来看，公司以自主研发的AIcare 技术体系为核心，将AI能力应用于健康内容生成、风险评估、智 能承保、理赔审核及用户运营等关键场景，显著提升服务效率与转化能力。在此基础上，轻松健康构建 起覆盖"检、医、药、康、险"的全链条数字健康服务生态，实现健康管理与保险保障的深度融合。这一 模式被市场视为AI在健康产业中实现规模化、可持续落地的重要创新方向。 12月23日，轻松健康集团正式登陆港交所主板，上市首日股价表现强劲。开盘即高开后持续走强，盘中 一度拉升至近60港元，收盘58.7港元，较发行价上涨近160%，成交持续放量，成为当日港股市场资金 关注度较高的新股之一。 在上市前阶段，公司已显现出明显的资本热度。招股期间，轻松健康集团公开发售部分获得投资者踊跃 参与，认购倍数超1400倍，显示出一级市场对其商业模式与成长空间的高度认可。上市前一日的暗盘交 易中，股价同样表现亮眼，暗盘收盘涨幅超130%，资金热情在正式挂牌前已提前释放。 市场分析认为，轻松健康上市首日的强劲走势，并非单纯情绪推动，而是资本对"AI+健康"重大创新路 径的集中定价。与传统健康平台或单一保险科技公司不同，轻松健康通过人工智能技术深度嵌 ...

Core Viewpoint - The Hong Kong IPO market remains vibrant as the digital health service platform, Easy Health Group, successfully listed, reflecting strong market confidence and potential for long-term investment returns [1][2]. Group 1: IPO Performance - Easy Health Group officially listed on the Hong Kong main board on December 23, with a first-day closing price of HKD 58.7, marking a 158.82% increase from its IPO price of HKD 22.68 [2]. - The company achieved a global subscription oversubscription rate of 1421 times, indicating high investor interest and confidence in its future growth [2][3]. - The strong performance on the first trading day was supported by a pre-listing dark market trading surge of over 127% [2]. Group 2: Business Transformation and Financial Performance - Easy Health Group has successfully transitioned to a comprehensive health service model, with revenue reaching HKD 945 million in 2024, a year-on-year increase of 92.9% [4]. - For the first half of 2025, revenue further increased to HKD 656 million, reflecting an 84.7% year-on-year growth, significantly outpacing industry averages [4]. - The company ranks 10th in the domestic digital health service and health insurance market, and 7th in the digital health service market, indicating a solid industry position [4]. Group 3: Business Model and Ecosystem - The dual-driven model of "health services + insurance technology" has established a comprehensive ecosystem, allowing users to access a full range of services from health monitoring to insurance claims [6]. - The health service business has become the core growth engine, with a compound annual growth rate of 221.26% over the past three years, and its revenue share reached 76.7% in the first half of 2025 [5]. - The integration of AI technology enhances operational efficiency and customer acquisition, creating a unique service barrier and further collaboration between health services and insurance [8][9]. Group 4: Technological Advancements - Easy Health Group has registered 58 invention patents and 39 software copyrights, demonstrating its commitment to technological innovation [7]. - The AI Care 4.0 system empowers various core scenarios in health management and insurance services, showcasing the company's technological capabilities [7]. - The AI marketing platform has generated 12.9 million business leads, with the value contribution from AI models increasing from 1.5% in 2022 to 23.3% in 2024, highlighting the effectiveness of AI in enhancing business performance [8]. Group 5: Market Potential and User Engagement - The platform has registered 168.4 million users, with 60.4% belonging to the core health consumer group aged 20-45, indicating a strong user base for business monetization [10]. - The company boasts a high user retention rate of 92.2% after 13 months, reflecting the platform's strong appeal [10]. - The ongoing growth in user conversion rates and insurance uptake demonstrates the effectiveness of the company's AI-driven marketing and product matching capabilities [11].

12月23日，国内"AI+健康"赛道标杆企业轻松健康集团（股票代码：2661.HK）正式登陆港交所主板。 受市场对数字健康赛道的强烈看好及公司基本面支撑，股价开盘即迎来强势表现，开盘价报50港元，较 发行价高开120%。 作为港股市场稀缺的"全链条数字健康"标的，轻松健康集团的亮眼表现源于多重核心优势。用户层面， 平台累计注册用户已达1.684亿，其中60.4%为20-45岁核心健康消费群体，用户基础为业绩增长提供坚 实支撑。技术层面，自主研发的AIcare技术栈已广泛应用于内容创作、智能承保、理赔审核等核心场 景，AI模型贡献的线索价值持续提升，技术赋能成效显著。 财务数据同样亮眼，2024年公司营收同比增长92.9%至9.45亿元，2025年上半年营收再增84.7%至6.56亿 元，健康服务业务收入占比已达76.7%，成为绝对核心增长引擎。在当前港股新股市场分化加剧、稀缺 性标的受追捧的背景下，轻松健康集团凭借"AI技术+用户规模+业务闭环"的独特优势，成功吸引资金 聚焦，为后续股价表现奠定基础。保荐机构表示，公司所处赛道契合"健康中国"战略，未来增长确定性 强，有望成为港股数字健康板块的核心配置标的。 ...

作为港股市场稀缺的"全链条数字健康"标的，轻松健康集团的亮眼表现源于多重核心优势。用户层面， 平台累计注册用户已达1.684亿，其中60.4%为20-45岁核心健康消费群体，用户基础为业绩增长提供坚 实支撑。技术层面，自主研发的AIcare技术栈已广泛应用于内容创作、智能承保、理赔审核等核心场 景，AI模型贡献的线索价值持续提升，技术赋能成效显著。 财务数据同样亮眼，2024年公司营收同比增长92.9%至9.45亿元，2025年上半年营收再增84.7%至6.56亿 元，健康服务业务收入占比已达76.7%，成为绝对核心增长引擎。在当前港股新股市场分化加剧、稀缺 性标的受追捧的背景下，轻松健康集团凭借"AI技术+用户规模+业务闭环"的独特优势，成功吸引资金 聚焦，为后续股价表现奠定基础。保荐机构表示，公司所处赛道契合"健康中国"战略，未来增长确定性 强，有望成为港股数字健康板块的核心配置标的。 12月23日，国内"AI+健康"赛道标杆企业轻松健康集团(02661)正式登陆港交所主板。受市场对数字健康 赛道的强烈看好及公司基本面支撑，股价开盘即迎来强势表现，开盘价报50港元，较发行价高开 120%。 ...